Format
Sort by
Items per page

Send to

Choose Destination

Best matches for GALSULFASE/TU:

Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. Brunelli MJ et al. Cochrane Database Syst Rev. (2016)

Galsulfase. Hopwood JJ et al. Nat Rev Drug Discov. (2006)

Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI. Harmatz PR et al. J Inherit Metab Dis. (2014)

Search results

Items: 1 to 20 of 41

1.

Family study of a novel mutation of mucopolysaccharidosis type VI with a severe phenotype and good response to enzymatic replacement therapy: Case report.

Ley-Martos M, Guerrero JM, Lucas-Javato M, Remón-García C, García-Lozano JR, Colón C, Crujeiras P, Rodrigues D, Paúl-Sánchez P, Macher HC.

Medicine (Baltimore). 2018 Oct;97(42):e12872. doi: 10.1097/MD.0000000000012872.

2.

The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

Harmatz P, Hendriksz CJ, Lampe C, McGill JJ, Parini R, Leão-Teles E, Valayannopoulos V, Cole TJ, Matousek R, Graham S, Guffon N, Quartel A; MPS VI Study Group.

Mol Genet Metab. 2017 Sep;122(1-2):107-112. doi: 10.1016/j.ymgme.2017.03.008. Epub 2017 Mar 31.

3.

Is premedication a necessity before galsulfase replacement therapy?

Ercan N, Bostanci IB, Ozmen S, Ertugrul A.

Ann Allergy Asthma Immunol. 2016 Aug;117(2):200-2. doi: 10.1016/j.anai.2016.06.002. Epub 2016 Jun 23. No abstract available.

PMID:
27346567
4.

A Desensitization Method to Maintain Enzyme Replacement Therapy in Mucopolysaccharidosis Type VI.

Kör D, Şeker Yilmaz B, Bulut FD, Önenli Mungan N, Ufuk Altıntaş D.

J Investig Allergol Clin Immunol. 2016;26(2):130-2. doi: 10.18176/jiaci.0030. No abstract available.

5.

Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.

Brunelli MJ, Atallah ÁN, da Silva EM.

Cochrane Database Syst Rev. 2016 Mar 4;3:CD009806. doi: 10.1002/14651858.CD009806.pub2. Review.

PMID:
26943923
6.

Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.

Ruane T, Haskins M, Cheng A, Wang P, Aguirre G, Knox VW 4th, Qi Y, Tompkins T, O'Neill CA.

Mol Genet Metab. 2016 Feb;117(2):157-63. doi: 10.1016/j.ymgme.2015.10.006. Epub 2015 Oct 21.

7.

[Management of mucopolysaccharidosis type VI in adults].

Muačević-Kataneć D, Pećin I, Šimić I, Fumić K, Potočki K, Šućur N, Reiner Ž; Croation Society for Rare Diseases, Croatian Medical Association.

Lijec Vjesn. 2015 Jul-Aug;137(7-8):213-5. Croatian.

PMID:
26502669
8.

Enzymes approved for human therapy: indications, mechanisms and adverse effects.

Baldo BA.

BioDrugs. 2015 Feb;29(1):31-55. doi: 10.1007/s40259-015-0116-7. Review.

PMID:
25648140
9.

[Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy].

Politei J, Schenone A, Blanco M, Szlago M.

Arch Argent Pediatr. 2014 Jun;112(3):258-62. doi: 10.1590/S0325-00752014000300011. Spanish.

10.

Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.

Giugliani R, Lampe C, Guffon N, Ketteridge D, Leão-Teles E, Wraith JE, Jones SA, Piscia-Nichols C, Lin P, Quartel A, Harmatz P.

Am J Med Genet A. 2014 Aug;164A(8):1953-64. doi: 10.1002/ajmg.a.36584. Epub 2014 Apr 24.

11.

Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.

Muenzer J.

Mol Genet Metab. 2014 Feb;111(2):63-72. doi: 10.1016/j.ymgme.2013.11.015. Epub 2013 Dec 11. Review.

12.

Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI.

Harmatz PR, Garcia P, Guffon N, Randolph LM, Shediac R, Braunlin E, Lachman RS, Decker C.

J Inherit Metab Dis. 2014 Mar;37(2):277-87. doi: 10.1007/s10545-013-9654-7. Epub 2013 Oct 10.

13.

Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases.

Jurecka A, Malinova V, Tylki-Szymańska A.

Mol Genet Metab. 2014 Feb;111(2):212-3. doi: 10.1016/j.ymgme.2013.08.019. Epub 2013 Sep 6. No abstract available.

PMID:
24060239
14.

Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.

Brands MM, Hoogeveen-Westerveld M, Kroos MA, Nobel W, Ruijter GJ, Özkan L, Plug I, Grinberg D, Vilageliu L, Halley DJ, van der Ploeg AT, Reuser AJ.

Orphanet J Rare Dis. 2013 Apr 4;8:51. doi: 10.1186/1750-1172-8-51.

15.

Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI.

Horovitz DD, Magalhães TS, Acosta A, Ribeiro EM, Giuliani LR, Palhares DB, Kim CA, de Paula AC, Kerstenestzy M, Pianovski MA, Costa MI, Santos FC, Martins AM, Aranda CS, Correa Neto J, Holanda GB, Cardoso L Jr, da Silva CA, Bonatti RC, Ribeiro BF, Rodrigues Mdo C, Llerena JC Jr.

Mol Genet Metab. 2013 May;109(1):62-9. doi: 10.1016/j.ymgme.2013.02.014. Epub 2013 Mar 5.

16.

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy.

Braunlin E, Rosenfeld H, Kampmann C, Johnson J, Beck M, Giugliani R, Guffon N, Ketteridge D, Sá Miranda CM, Scarpa M, Schwartz IV, Leão Teles E, Wraith JE, Barrios P, Dias da Silva E, Kurio G, Richardson M, Gildengorin G, Hopwood JJ, Imperiale M, Schatz A, Decker C, Harmatz P; MPS VI Study Group.

J Inherit Metab Dis. 2013 Mar;36(2):385-94. doi: 10.1007/s10545-012-9481-2. Epub 2012 Jun 5.

17.

Therapy for the mucopolysaccharidoses.

Valayannopoulos V, Wijburg FA.

Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v49-59. doi: 10.1093/rheumatology/ker396. Review.

PMID:
22210671
18.

Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).

Hendriksz CJ, Giugliani R, Harmatz P, Lampe C, Martins AM, Pastores GM, Steiner RD, Leão Teles E, Valayannopoulos V; CSP Study Group.

J Inherit Metab Dis. 2013 Mar;36(2):373-84. doi: 10.1007/s10545-011-9410-9. Epub 2011 Nov 30.

PMID:
22127392
19.

Abnormal granulation of blood granulocytes in mucopolysaccharidosis VI-a case report.

Krishnagiri C, Ajanahalli RR, Kashyap S, Anegundi R, Boranaik L.

Ann Diagn Pathol. 2013 Feb;17(1):137-9. doi: 10.1016/j.anndiagpath.2011.07.009. Epub 2011 Nov 4.

PMID:
22056033
20.

Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.

Furujo M, Kubo T, Kosuga M, Okuyama T.

Mol Genet Metab. 2011 Dec;104(4):597-602. doi: 10.1016/j.ymgme.2011.08.029. Epub 2011 Aug 28.

PMID:
21930407

Supplemental Content

Loading ...
Support Center